Analysts expect InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) to report $-0.16 EPS on March, 9.They anticipate $0.05 EPS change or 23.81% from last quarter’s $-0.21 EPS. After having $-0.28 EPS previously, InVivo Therapeutics Holdings Corp.’s analysts see -42.86% EPS growth. The stock decreased 1.50% or $0.01 during the last trading session, reaching $0.51. About 66,991 shares traded. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) has declined 65.27% since February 14, 2017 and is downtrending. It has underperformed by 81.97% the S&P500.
Tower International, Inc. manufactures and sells engineered automotive structural metal components and assemblies primarily for original equipment manufacturers. The company has market cap of $564.53 million. It operates in two divisions, North America and Europe. It has a 8.36 P/E ratio. The firm offers body structures and assemblies comprising structural metal components, including body pillars, roof rails, and side sills; and Class A surfaces and assemblies that consist of body sides, hoods, doors, fenders, and pickup truck boxes.
The stock increased 8.70% or $2.2 during the last trading session, reaching $27.5. About 90,856 shares traded or 1.49% up from the average. Tower International, Inc. (TOWR) has risen 16.50% since February 14, 2017 and is uptrending. It has underperformed by 0.20% the S&P500.
Towle & Co holds 3.13% of its portfolio in Tower International, Inc. for 1.08 million shares. Zpr Investment Management owns 70,336 shares or 2.9% of their US portfolio. Moreover, Smith Graham & Co. Investment Advisors Lp has 0.99% invested in the company for 346,146 shares. The Missouri-based Sterneck Capital Management Llc has invested 0.88% in the stock. Buckhead Capital Management Llc, a Georgia-based fund reported 145,705 shares.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company has market cap of $17.56 million. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. It currently has negative earnings.